BeiGene Profit Margin

BeiGene (BGNE) currently reports a profit margin of 10.7% as of June 2026. That compares with -3.89% in the prior-year period — up 374.7% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore BeiGene's profit margin history and peer comparisons.

BeiGene's profit margin increased from -3.89% to 10.7% — a 374.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BeiGene's profit margin of 10.7% is lower than the Healthcare sector average of 14.34%. That is roughly 25.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but BeiGene's current 10.7% should be judged against Healthcare norms (sector average: 14.34%) and against BGNE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 10.7%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for BeiGene, and consider following BGNE for alerts when major investors trade the stock.